As of November 6, 2026, Tenax Therapeutics, Inc. is a publicly traded company (Nasdaq: TENX); its largest reported holder is ADAR1 Capital, with 14% on Schedule 13G of September 8, 2026, then RTW Investments (9.9%) (Schedule 13G, September 8, 2026).
Is this your company?
About to sign with, pay or invest in Tenax Therapeutics, Inc.? See the free Snapshot first.
Free to see. No signup.
Is Tenax Therapeutics, Inc. a real, registered company?
- Tenax Therapeutics Inc files with the SEC under CIK 34956 (its SEC filings).
- Its shares are listed under the ticker TENX on Nasdaq (SEC company record).
- Incorporated in Delaware; business address in Chapel Hill, North Carolina, as its SEC filings state.
- Court and bankruptcy records: see Before you sign or pay below.
Before you sign or pay
- Court and bankruptcy: No federal court case or bankruptcy filing found under TENAX THERAPEUTICS, INC. in our court records and SEC 8-K records (as of 2026-11-06).
- Ownership: 5%+ holders are reported on Schedule 13D or 13G; the latest names BlackRock (filed 2026-10-27).
Who are Tenax Therapeutics, Inc.'s owners and officers?
Tenax Therapeutics, Inc.: incorporated in Delaware; business address in Chapel Hill, North Carolina; industry Pharmaceutical Preparations (Schedule 13G/A, 2026-10-27).
Officers and directors, each with the role and the filing that names them:
- : Executive Officer, Director (Form D, 2024-08-23)
- : Executive Officer (Form D, 2024-08-23)
- : Director (Form D, 2024-08-23)
- : Director (Form D, 2024-08-23)
- : Director (Form D, 2024-08-23)
- : Director (Form D, 2024-08-23)
- : Executive Officer, Director (Form D, 2024-08-23)
- : Director (Form D, 2024-08-23)
| Report | Holder | Share |
|---|---|---|
| Schedule 13G/A, 2026-10-27 | Blackrock, Inc. | 7.5% |
| Schedule 13G/A, 2026-10-15 | Millennium Management LLC | 3.6% |
| Schedule 13G/A, 2026-10-13 | Sphera Funds Management LTD. | 7.09% |
| Schedule 13G/A, 2026-10-09 | Dellora Investments LP | 6.4% |
| Schedule 13G/A, 2026-09-11 | Ing Groep N.V. | 0% |
| Schedule 13G/A, 2026-09-08 | Fmr LLC | 1.4% |
| Schedule 13G, 2026-09-08 | Adar1 Capital Management, LLC | 14% |
| Schedule 13G, 2026-08-27 | Ing Groep N.V. | 7.05% |
| Schedule 13G, 2026-08-27 | Sphera Funds Management LTD. | 5.33% |
| Schedule 13G, 2026-08-18 | Millennium Management LLC | 5.8% |
| Schedule 13G/A, 2026-08-14 | Rtw Investments, LP | 9.9% |
| Schedule 13G/A, 2026-08-14 | Perceptive Advisors LLC | 4.5% |
Questions about who owns Tenax Therapeutics, Inc.
Who owns Tenax Therapeutics, Inc.?
On this page, 5 holders' latest ownership filings report 5% or more of Tenax Therapeutics, Inc.: Adar1 Capital Management, LLC (14%, Schedule 13G, filed 2026-09-08), Rtw Investments, LP (9.9%, Schedule 13G/A, filed 2026-08-14), Blackrock, Inc. (7.5%, Schedule 13G/A, filed 2026-10-27), Sphera Funds Management LTD. (7.09%, Schedule 13G/A, filed 2026-10-13) and Dellora Investments LP (6.4%, Schedule 13G/A, filed 2026-10-09).
Who are the largest shareholders of Tenax Therapeutics, Inc.?
By the share each holder's latest filing reports, the largest holders of Tenax Therapeutics, Inc. on this page are Adar1 Capital Management, LLC (14%), Rtw Investments, LP (9.9%) and Blackrock, Inc. (7.5%).
When did Adar1 Capital Management, LLC buy into Tenax Therapeutics, Inc.?
The filings give report dates, not purchase dates. The earliest filing from Adar1 Capital Management, LLC on this page is the Schedule 13G, filed 2026-09-08, reporting 14%.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 12 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Want the whole picture on Tenax Therapeutics, Inc.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Tenax Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Tenax Therapeutics, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
18 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Which insiders own Tenax Therapeutics, Inc. shares?
Directors, officers and holders of 10% or more report their shares on Forms 3, 4 and 5. Each line is the latest such report, largest holding first.
- ADAR1 Capital, a 10% owner: 7,447,000 shares (16.4% of shares outstanding), held indirectly (the form names the holder only in its footnotes), on a joint filing (Form 4, 2026-10-21).
- , a 10% owner: 7,447,000 shares (16.4% of shares outstanding), held indirectly (the form names the holder only in its footnotes), on a joint filing (Form 4, 2026-10-21).
- Dellora Investments LP, a 10% owner: 351,071 shares (0.77% of shares outstanding), held indirectly (the form names the holder only in its footnotes) (Form 3, 2025-01-10).
- , a director: 55,274 shares (0.12% of shares outstanding) (Form 4, 2026-09-17).
- , the chief executive and a director: 22,174 shares (0.05% of shares outstanding) (Form 4, 2026-09-15).
Shares outstanding: 45,536,448 as of 2026-10-31, from the company's latest SEC cover page.
How much has Tenax Therapeutics, Inc. raised?
| Filed | Sold | Offered |
|---|---|---|
| Form D, 2024-08-23 | $99.68M | $175M |
Keep reading
More on Tenax Therapeutics, Inc. and the records around it.
Tenax Therapeutics, Inc. elsewhere on the record
- 5%+ stake filings Oct 2026
Companies that share a holder
- Dellora Investments Master Fund LP also filed stake reports on 1 other company: Rezolute, Inc. (Aug 2026)
- ING Groep N.V. also filed stake reports on 1 other company: NEOGEN CORP (Dec 2025)
- Sphera Funds Management Ltd. also filed stake reports on 2 other companies: Outlook Therapeutics, Inc. (Feb 2026), ProMIS Neurosciences Inc. (Feb 2026)
Related pages
Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.
Not for employment, credit, insurance or tenancy decisions.
Cite this page
https://mentionfox.com/who-owns/tenax-therapeutics